Free tool
FAERS Monitor: Monistat 3 Combination Pack
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020670 or its brand name (Monistat 3 Combination Pack, Miconazole Nitrate). Reports on generic versions are filed under their own applications.
Reports
5,389
Serious
994
18% of reports
Hospitalization
357
Death reported
91
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vulvovaginal burning sensation1,784
- drug ineffective998
- vulvovaginal pain945
- vulvovaginal pruritus572
- condition aggravated498
- vulvovaginal discomfort440
- vaginal haemorrhage415
- vulvovaginal swelling306
- pain155
- hypersensitivity141
- burning sensation136
- pruritus132
- vaginal discharge122
- off label use113
- abdominal pain112
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 23 |
| 2005 | 24 |
| 2006 | 27 |
| 2007 | 21 |
| 2008 | 48 |
| 2009 | 76 |
| 2010 | 54 |
| 2011 | 59 |
| 2012 | 83 |
| 2013 | 27 |
| 2014 | 38 |
| 2015 | 46 |
| 2016 | 473 |
| 2017 | 428 |
| 2018 | 516 |
| 2019 | 416 |
| 2020 | 461 |
| 2021 | 517 |
| 2022 | 376 |
| 2023 | 290 |
| 2024 | 416 |
| 2025 | 456 |
| 2026 | 514 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,770 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vulvovaginal burning sensationSignal | 1,784 | 1610.7 | 1534.9 | 2,031,468 |
| vulvovaginal painSignal | 945 | 952.0 | 891.3 | 721,242 |
| vulvovaginal swellingSignal | 306 | 785.3 | 696.6 | 198,927 |
| vulvovaginal pruritusSignal | 572 | 496.7 | 457.2 | 250,666 |
| vulvovaginal discomfortSignal | 440 | 431.4 | 392.4 | 169,783 |
| vaginal dischargeSignal | 122 | 47.6 | 39.9 | 5,456 |
| vaginal haemorrhageSignal | 415 | 37.7 | 34.3 | 14,664 |
| burning sensationSignal | 136 | 7.6 | 6.4 | 772 |
| condition aggravatedSignal | 498 | 6.4 | 5.9 | 2,294 |
| hypersensitivitySignal | 141 | 3.0 | 2.5 | 183 |
| drug ineffectiveSignal | 998 | 3.0 | 2.8 | 1,376 |
| abdominal pain | 112 | 1.9 | 1.6 | 46 |
| pruritus | 132 | 1.3 | 1.1 | 11 |
| pain | 155 | 1.0 | 0.8 | 0 |
| off label use | 113 | 0.5 | 0.4 | 57 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.